RHS 0.00% 27.5¢ rhs limited

News: Reproductive Health Science products to be sold in Israel, southern Africa

  1. Reproductive Health Science (ASX:RHS) has now entered into key new markets by signing a 3-year exclusive distribution agreements with distributors based in Israel and South Africa, for the sale of its lead product EmbryoCellect™.

    EmbryoCellect™ is a pre-implantation genetic screening (PGS) kit designed to increase the chance of a successful In-Vitro Fertilisation (IVF) cycle.

    Launched in 2014, EmbryoCellectTM contains reagents for 20 tests at a list price of AUD$3,600 per kit.

    The international IVF rate varies from country to country but has been estimated to continue to grow at 10% per annum through to 2020.

    Israel is a key market with around 32,000 cycles of IVF are undertaken each year, as the Israeli Government provides free, unlimited IVF procedures for women up to the age of 45 for up to two babies.

    This policy has made Israel the biggest user of IVF per capita in the world, where 4% of children are IVF babies, compared to 1% in the U.S.

    RHS will team with Al-Rad Medical for the sale of EmbryoCellect™ in Israel and the Palestinian Authority.

    In Southern Africa, the company signed an agreement with Delfran Pharmaceuticals in the South African Development Community (SADC) countries.

    These include Angola, Botswana, Democratic Republic of Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, United Republic of Tanzania, Zambia and Zimbabwe.

    The South African Register of Assisted Reproductive Techniques Committee reports that in 2011 there were more than 5,600 IVF cycles conducted by the 14 participating South African IVF clinics, representing an almost 15% increase from 2010.

     

 
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.